US Edition
AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
- On June 30, 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics, including its lead program CPTX2309 and proprietary tLNP platform.
- AbbVie sought to expand its immunology pipeline as Humira faces biosimilar competition and Capstan develops novel in vivo CAR-T therapies for autoimmune diseases.
- CPTX2309 delivers mRNA via lipid nanoparticles to reprogram T cells to deplete pathogenic B cells without lymphodepletion, with a Phase 1 trial enrolling healthy volunteers underway.
- AbbVie will provide up to $2.1 billion in cash upfront as part of the acquisition, and company leadership highlighted that initial Phase 1 results demonstrate rapid and substantial B-cell depletion, supporting the clinical potential of CPTX2309.
- The acquisition positions AbbVie to develop scalable, disease-modifying immunology therapies with in vivo cell engineering, potentially reshaping autoimmune disease treatment.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
1
Center
7
Right
MedCity NewsReposted by 
Dealbreaker
DealbreakerAbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.
Coverage Details
Total News Sources20
Leaning Left1Leaning Right0Center7Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
13%
C 88%
Factuality
To view factuality data please Upgrade to Premium
